Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 7, 2007, Pages 963-969

  Vanni, T ^a   Morejon K M ^a   Santana, R C ^a   de Melo, L ^a   Ferrao S B R L ^a   Amorim, A P ^a   Gaspar, G G ^a   Ponzi, C C ^a   Golin, N A ^a   Custodio F L ^a   Marangoni, A T D ^a   Campos, C P ^a   Fonseca, B A L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

AIDS; Antiretroviral treatment; Efavirenz; Highly active antiretroviral therapy; HIV; Nelfinavir

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY; ARTICLE; BRAZIL; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; SIDE EFFECT; TERTIARY HEALTH CARE; TREATMENT RESPONSE; VIRUS LOAD;

EID: 34547768212     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2007000700011     Document Type: Article

References (24)

1. Teixeira PR, Vitoria MA, Barcarolo J. Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS 2004; 18 (Suppl) 3: S5-S7.
2. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.Ann Intern Med 2000; 133: 21-30.
3. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13: 1099-1107.
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
5. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
6. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Komer T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-F70.
7. Hisch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR. Antiretroviral drug resistance test in adult HIV-1 infection: recommendation of an International AIDS Society-USA Panel. J Am Med Assoc 2000; 283: 2417-2426.
8. Erickson JW, Gulnik SV, Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 1999; 13 (Suppl A): S189-S204.
9. Stoll M, Claes C, Schulte E, Graf von der Schulenburg JM, Schmidt RE. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res 2002; 7: 463-471.
10. Staszewski S, Morales-Ramirez J,Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-1873.
11. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2293-2303.
12. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV-infection. N Engl J Med 2001; 345: 398-407.
13. lvers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor -settings: a meta-analysis of published literature. Clin Infect Dis 2005; 41: 217-224.
14. Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among poents who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2004; 36: 967-971.
15. The Brazilian Guideline for the antiretroviral treatment of HIV-infected adults. 2001. http://www.aids.gov.br. Accessed December 1, 2006.
16. Brazilian National Program of STD and AIDS homepage (PN DST/AIDS). http://www.aids.gov.br/final/dados/BOLETIM2.pdf. Accessed December 1, 2006.
17. Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet 2005; 365: 1657-1661.
18. The Infectious Diseases Society of America Treatment of Opportunistic Infections Guidelines - December 7, 2004. http://aidsinfo.nih.gov/ Guidelines/. Accessed December 1, 2006.
19. Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS 2001; 15: 1679-1686.
20. Pulido F, Arribas JR, Miro JM, Costa MA, Gonzalez J, Rubio R, et al. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr 2004; 35: 343-350.
21. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20: 2051-2064.
22. Walmsley S, Berstein B, King M, Arribas J, Beall G, Ruane P. Lopinavir-ritonavir versus neifinavir for the initial treatment of the HIV infection. New Engl J Med 2002; 346: 2039-2046.
23. Perez-Elias W, Moreno A, Moreno S, Antela A, Dronda F, Munoz V, et al. Differences in durability of treatment with initial PI-based regimens. HIV Clin Trials 2003; 4: 391-399.
24. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999; 13: 2075-2082.